These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 16945078

  • 1. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
    Paton NI, Sangeetha S, Earnest A, Bellamy R.
    HIV Med; 2006 Jul; 7(5):323-30. PubMed ID: 16945078
    [Abstract] [Full Text] [Related]

  • 2. The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART).
    Taye B, Shiferaw S, Enquselassie F.
    Ethiop Med J; 2010 Jan; 48(1):1-10. PubMed ID: 20607992
    [Abstract] [Full Text] [Related]

  • 3. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings.
    Argemi X, Dara S, You S, Mattei JF, Courpotin C, Simon B, Hansmann Y, Christmann D, Lefebvre N.
    AIDS; 2012 Jun 01; 26(9):1161-6. PubMed ID: 22472856
    [Abstract] [Full Text] [Related]

  • 4. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Jun 01; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 5. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.
    HIV Med; 2007 Jan 01; 8(1):46-54. PubMed ID: 17305932
    [Abstract] [Full Text] [Related]

  • 6. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 7. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May 01; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 8. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
    Ding YY, Jia WQ, Wang JS, Dong SL, Yang QH, Zhou RY, Qu SX, Lu LX, Wei J, Qiao XC, Gao MY, Guo XL, Zhang TJ, Wu ZY, He N.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec 01; 29(12):1176-80. PubMed ID: 19173958
    [Abstract] [Full Text] [Related]

  • 9. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.
    AIDS; 2006 May 12; 20(8):1181-9. PubMed ID: 16691070
    [Abstract] [Full Text] [Related]

  • 10. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 11. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.
    J Infect Dis; 2004 Sep 15; 190(6):1046-54. PubMed ID: 15319852
    [Abstract] [Full Text] [Related]

  • 12. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 13. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.
    AIDS; 2007 Jan 30; 21(3):351-9. PubMed ID: 17255742
    [Abstract] [Full Text] [Related]

  • 14. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Jan 30; 12(6):931-9. PubMed ID: 17926647
    [Abstract] [Full Text] [Related]

  • 15. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S, Alary M.
    HIV Med; 2009 Nov 30; 10(10):640-6. PubMed ID: 19659945
    [Abstract] [Full Text] [Related]

  • 16. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst HA, Brodt HR.
    Br J Haematol; 2004 May 30; 125(4):455-62. PubMed ID: 15142115
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
    Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.
    Arch Intern Med; 2008 Jan 14; 168(1):86-93. PubMed ID: 18195200
    [Abstract] [Full Text] [Related]

  • 18. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 19. Impact on weight and height with the use of HAART in HIV-infected children.
    Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA.
    Pediatr Infect Dis J; 2007 Apr 15; 26(4):334-8. PubMed ID: 17414398
    [Abstract] [Full Text] [Related]

  • 20. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar 15; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.